Juxtapid FDA Approval History
FDA Approved: Yes (First approved December 21, 2012)
Brand name: Juxtapid
Generic name: lomitapide
Dosage form: Capsules
Company: Aegerion Pharmaceuticals Inc.
Treatment for: High Cholesterol, Familial Homozygous
Juxtapid (lomitapide) is a microsomal triglyceride transfer protein inhibitor indicated for the treatment of patients with homozygous familial hypercholesterolemia.
Development timeline for Juxtapid
|Dec 26, 2012||Approval FDA Approves Juxtapid - New Orphan Drug for Rare Cholesterol Disorder|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.